Skip to main content

Accendra Health, Inc.

corporate_fare Company Profile

Accendra Health, Inc.

ACH·NYSE·Trade & Services·CIK 0000075252

General Accendra Health, Inc. is a nationwide provider of products, technology, and services that supports health beyond the hospital. The company connects patients, providers, and insurers, delivering solutions to promote better health outcomes and improve quality of life for people with chronic, complex, and acute health conditions. Its trusted brands, Apria and Byram Healthcare, have nearly 90 years of combined experience. The company is headquartered in Richmond, Virginia. On October 7, 2025, the company entered into an Equity Purchase Agreement to sell its Products & Healthcare Services (P&HS) business for an aggregate of $375 million in cash, subject to certain adjustments. This sale was completed on December 31, 2025. The company has retained a 5% equity interest in the P&HS business. General Accendra Health provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies. It is a leading provider of integrated home healthcare equipment and related services in the U.S. The company offers a comprehensive range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services).

Accendra Health, Inc. (NYSE:ACH) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 23 items for ACH at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholders to Vote on Significant Equity Plan Expansion and Executive Compensation
  • Accendra Health Reports $1.1B Net Loss, Shifts to Deficit Equity Amid Major Divestiture and Contract Termination
  • Accendra Health Reports Q4/FY25 Results, Completes P&HS Sale, and Issues Lower 2026 Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.76B
Net Income
-$1.1B
Diluted EPS
-$14.31
Gross Profit
$1.29B
Operating Income
$27.46M
Cash & Equivalents
$281.99M
Total Debt
$250M
Debt / Equity
-0.54×
Net Margin
-39.8%
Shares Outstanding
76.39M sh
Source: 10-K · filed 2026-02-20 · accession 0001104659-26-018169
$0.2581 +1.53% today
52-week range · as of 2026-10-30 $0.191 – $5.24
Market cap
$19.56M
Volume
1.6M (0.8× avg)
3-mo avg 2M
Live data · 2026-11-02 08:30 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ACH - Filings & News (Page 2)

ACH
Apr 02, 2026, 6:25 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $0.2581 info
Change: -$2.09 (-89%) info
Market Cap: $19.565M info
ACH
Feb 20, 2026, 4:19 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.61
Real-time Price: $0.2581 info
Change: -$2.35 (-90%) info
Market Cap: $19.565M info
ACH
Feb 19, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.40
Real-time Price: $0.2581 info
Change: -$2.14 (-89%) info
Market Cap: $19.565M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets